Scottsdale, AZ – December 13, 2019 –Systems Oncology, an AI-based biopharmaceutical company, is presenting a poster at the San Antonio Breast Cancer Symposium 2019. The poster will highlight ErSO, an orally bioavailable, first-in-class therapy for the treatment of resistant ER alpha positive breast cancer. ErSO triggers an immunogenic necrotic cell death via a novel hyperactivation of the anticipatory Unfolding Protein Response (a-UPR) without ER alpha degradation.
Full Poster: Quantitative Regression of Estrogen Receptor Alpha Positive Breast Cancer
Session: New Drugs and Mechanisms
Board #: P5-05-16
Time: December 13rd , 2019, 5PM-7PM
About Systems Oncology
Systems Oncology (SO) combines multi-scalar systems modeling with machine learning and big-data to uncover breakthrough insights into cancer biology and expose new therapeutic vulnerabilities. These discoveries are then used to better develop truly novel therapeutic agents. SO has the experience and knowhow needed to intelligently translate scientific insights into smarter clinical development strategies and faster registration paths. It then partners with leading pharmaceutical companies to accelerate the development of breakthrough cancer treatments. Fundamental to the SO approach is a next-generation AI platform for translating scientific insights into innovative cancer therapies with unprecedented speed, scale, and precision.